0000950170-24-017091.txt : 20240220
0000950170-24-017091.hdr.sgml : 20240220
20240220160546
ACCESSION NUMBER: 0000950170-24-017091
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240215
FILED AS OF DATE: 20240220
DATE AS OF CHANGE: 20240220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kelly Thomas Patrick
CENTRAL INDEX KEY: 0001410514
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 24653233
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, INC.
STREET 2: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
ownership.xml
4
X0508
4
2024-02-15
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001410514
Kelly Thomas Patrick
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM
MA
02451
false
true
false
false
Chief Financial Officer
false
Common Stock
2024-02-15
4
A
false
17275
0
A
83360
D
Common Stock
2024-02-16
4
S
false
3010
15.6177
D
80350
D
Stock Option (Right to Buy)
15.92
2024-02-15
4
A
false
69100
0
A
2034-02-14
Common Stock
69100
69100
D
The reporting person was awarded 17,275 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2025, February 15, 2026 and February 15, 2027.
This sale was to cover tax liabilities in the vesting of RSUs.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6175 to $15.6177, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024.
/s/ Jeffrey M. Held, Attorney-in-Fact
2024-02-20